J Rheumatol:抗中性粒细胞胞浆抗体相关性血管炎患者的甲状腺疾病患病率升高

2018-04-01 xiangting MedSci原创

AAV患者甲状腺疾病的患病率高于一般人群。而这并不能归因于抗甲状腺药物。

抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)由于抗甲状腺药物,而与甲状腺疾病有关。这项研究评估了AAV患者中甲状腺疾病的患病率。

研究人员对1991年至2014年间确诊的279例AAV患者的临床资料进行了分析。

结果发现,21.5%的患者有甲状腺疾病,但只有2例此前接受过丙基硫氧嘧啶治疗。在甲状腺疾病组中,女性患者、抗髓过氧化物酶抗体阳性患者和伴肾脏疾病患者的比例更高。

这项研究数据显示AAV患者甲状腺疾病的患病率高于一般人群。而这并不能归因于抗甲状腺药物。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837481, encodeId=cd6a183e48197, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Aug 16 12:35:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250533, encodeId=fc371250533a1, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263186, encodeId=89191263186c8, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296664, encodeId=8c25129666429, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556292, encodeId=36b2155629218, content=<a href='/topic/show?id=8efc5515523' target=_blank style='color:#2F92EE;'>#抗中性粒细胞胞浆抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55155, encryptionId=8efc5515523, topicName=抗中性粒细胞胞浆抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57dd14737290, createdName=oliver174, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837481, encodeId=cd6a183e48197, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Aug 16 12:35:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250533, encodeId=fc371250533a1, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263186, encodeId=89191263186c8, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296664, encodeId=8c25129666429, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556292, encodeId=36b2155629218, content=<a href='/topic/show?id=8efc5515523' target=_blank style='color:#2F92EE;'>#抗中性粒细胞胞浆抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55155, encryptionId=8efc5515523, topicName=抗中性粒细胞胞浆抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57dd14737290, createdName=oliver174, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837481, encodeId=cd6a183e48197, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Aug 16 12:35:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250533, encodeId=fc371250533a1, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263186, encodeId=89191263186c8, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296664, encodeId=8c25129666429, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556292, encodeId=36b2155629218, content=<a href='/topic/show?id=8efc5515523' target=_blank style='color:#2F92EE;'>#抗中性粒细胞胞浆抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55155, encryptionId=8efc5515523, topicName=抗中性粒细胞胞浆抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57dd14737290, createdName=oliver174, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837481, encodeId=cd6a183e48197, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Aug 16 12:35:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250533, encodeId=fc371250533a1, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263186, encodeId=89191263186c8, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296664, encodeId=8c25129666429, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556292, encodeId=36b2155629218, content=<a href='/topic/show?id=8efc5515523' target=_blank style='color:#2F92EE;'>#抗中性粒细胞胞浆抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55155, encryptionId=8efc5515523, topicName=抗中性粒细胞胞浆抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57dd14737290, createdName=oliver174, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837481, encodeId=cd6a183e48197, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Aug 16 12:35:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250533, encodeId=fc371250533a1, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263186, encodeId=89191263186c8, content=<a href='/topic/show?id=581e8968859' target=_blank style='color:#2F92EE;'>#血管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89688, encryptionId=581e8968859, topicName=血管炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=909c71, createdName=shijzhiewnjhch, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296664, encodeId=8c25129666429, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556292, encodeId=36b2155629218, content=<a href='/topic/show?id=8efc5515523' target=_blank style='color:#2F92EE;'>#抗中性粒细胞胞浆抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55155, encryptionId=8efc5515523, topicName=抗中性粒细胞胞浆抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57dd14737290, createdName=oliver174, createdTime=Tue Apr 03 01:35:00 CST 2018, time=2018-04-03, status=1, ipAttribution=)]

相关资讯

Circulation:川崎病的诊断、治疗和长期管理——AHA医疗卫生人员的科学声明

川崎病是一种儿童时期的急性血管炎,在约25%的未治疗病例中,可造成冠状动脉瘤。在发达国家,已经广泛对其报道,并且成为发达国家儿童获得性心脏病的主要原因。2017年4月,发表在《Circulation》的一项美国心脏病协会卫生专业人员的科学声明阐述了川崎病的诊断、治疗和长期管理。

Rheumatology (Oxford):PACNS成人患者:维持治疗有益于长期结局

原发性中枢神经系统血管炎(PACNS)是一种罕见、病因尚不明确的血管炎。2017年10月,发表在《Rheumatology (Oxford)》的一项长期随访研究调查了诱导后维持治疗对PACNS成人患者结局的影响。结果表明,成人PACNS维持治疗与较好的功能结局和较低的复发率相关。

BMC Nephrol:ANCA相关性血管炎的早期诊断至关重要

摘要 背景:ANCA相关性血管炎急性期之前常有前驱期。本研究目的是分析肾损伤与前驱期长短的相关性。

BMC Immunol:RF是ANCA相关性血管炎病情活动的炎症标志物

摘要 背景:有些ANCA相关性血管炎(AAV)患者也有类风湿因子(RF)阳性。然而AAV患者中其临床意义未明。本研究的目的是阐明AAV患者中存在RF与患者临床特点的相关性。

Neurology:血管炎相关视网膜中央动脉闭塞1例

45岁,女性。既往皮肤狼疮,抗磷脂抗体阴性,平日预防性抗凝治疗。本次表现为左眼急性和严重无痛性视力丧失。